South and Central America Anti-Infective Agents Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type, Range, Route of Administration, Indication, and Distribution Channel

The South & Central America anti-infective agents market is projected to grow from US$ 5,713.39 million in 2022 to US$ 6,498.70 million by 2028, at a CAGR of 2.2% during the forecast period.

In South & Central America, the market exhibits growth opportunities with progressive developments in Brazil, such as growing medical tourism and an increasing number of government initiatives to create awareness about anti-infective agents. The growing prevalence of infectious diseases is a major concern among the Brazilian population, thereby increasing the demand for anti-infective agents. These factors stimulate the growth of the anti-infective agent market in this region.

A few major countries contributing to the growth of the anti-infective agents market include Chile, Colombia, Peru, and Bolivia. The aging population, high prevalence of osteoporosis, and growing number of orthopedic surgeries are prime factors for the market growth. The presence of international healthcare technology players further strengthens the market's growth in the region. For instance, Surbiton reaffirms its position as Argentina's flagship Company in the field of medical devices of international quality. Moreover, the company has an active presence in several countries, including Peru, Colombia, and Argentina. Such developments are estimated to contribute to the growth of the Rest of the South & Central America anti-infective agents anti-infective agents market during the forecast period.

Vendors can attract new customers and expand their footprints in emerging markets with new features and technologies. This factor is likely to drive the South & Central America anti-infective agents market at a good CAGR during the forecast period.

South & Central America Anti-Infective Agents Market Segmentation

The South & Central America anti-infective agents market is segmented based on type, range, route of administration, indication, distribution channel, and country.

• Based on type, the market is segmented into anti-bacterial, anti-viral, anti-fungal, and others. The anti-viral segment is expected to account for the largest market share by the end of 2022.
• Based on range, the market is segmented into broad spectrum and narrow spectrum. By the end of 2022, the narrow spectrum segment will likely hold a larger market share.
• Based on route of administration, the market is segmented into topical, oral, IV, and others. By the end of 2022, the IV segment is likely to hold the largest market share.
• Based on indication, the market is segmented into HIV, tuberculosis, respiratory infection, pneumonia, and others. In 2022, the others segment is projected to hold the largest share of the market.
• Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, e-commerce, and others. By the end of 2022, the hospital pharmacies segment is likely to hold the largest market share.
• Based on country, the market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil is expected to hold the largest market share by the end of 2022.

Abbott; Allergan Plc.; Astellas Pharma Inc.; Bayer AG; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Merck & Co., Inc.; and Novartis AG are the leading companies in the South & Central America anti-infective agents market.